FORZINITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FORZINITY (FORZINITY).
FORZINITY (sodium-glucose cotransporter-2 inhibitor) inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism via CYP3A4. |
| Excretion | Primarily renal excretion (60-70% as unchanged drug) with biliary/fecal elimination accounting for 20-30%. |
| Half-life | Terminal elimination half-life is 12-18 hours; clinically significant for once-daily dosing in most patients. |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | 0.5-0.8 L/kg; indicates distribution into total body water, not extensive tissue binding. |
| Bioavailability | Oral: 60-70% (first-pass metabolism). |
| Onset of Action | Oral: 2-4 hours; intravenous: 15-30 minutes. |
| Duration of Action | 24-36 hours; allows once-daily dosing; extended duration supports consistent therapeutic effect. |
| Molecular Weight | 421.5 |
1.5 mg/kg intravenously every 4 weeks. For patients with body weight >100 kg, a fixed dose of 150 mg is recommended.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). For severe renal impairment (eGFR <30 mL/min/1.73 m²) or on dialysis, administer 1.5 mg/kg intravenously every 6 weeks. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate to severe hepatic impairment (Child-Pugh B or C), reduce dose to 1 mg/kg intravenously every 4 weeks. |
| Pediatric use | For children aged 2-12 years: 2 mg/kg intravenously every 4 weeks, maximum dose 100 mg. For adolescents >12 years: same as adult dosing. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor renal function and consider age-related decline in creatinine clearance. |
| 1st trimester | Embryotoxic in animal studies; avoid use unless benefit outweighs risk. |
| 2nd trimester | Fetal growth restriction and oligohydramnios reported; monitor amniotic fluid volume. |
| 3rd trimester | Risk of neonatal complications including hypoglycemia and electrolyte disturbances; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for FORZINITY (FORZINITY).
| Placental transfer | Crosses placenta efficiently; fetal concentrations reach 50-80% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for potential adverse effects such as diarrhea or rash. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to FORZINITYSevere renal impairment (eGFR <30 mL/min)Concomitant use with strong CYP3A4 inhibitors
| Precautions | Ketoacidosis: May occur with euglycemia; assess for acidosis if symptoms present., Lower limb amputation: Increased risk, especially in patients with prior amputation, peripheral vascular disease, neuropathy, or diabetic foot ulcers., Hypotension: Risk is increased in patients with impaired renal function, elderly, or on diuretics., Acute kidney injury: Not recommended in patients with eGFR <30 mL/min/1.73 m2., Urosepsis and pyelonephritis: Urinary tract infections may become serious., Hypoglycemia: Concomitant use with insulin or insulin secretagogues may increase risk., Genital mycotic infections: Increased risk, especially in patients with history of infections. |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol intake as it may increase risk of ketoacidosis. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FORZINITY is contraindicated in pregnancy. Based on animal studies and mechanism of action, there is a high risk of teratogenicity. First trimester exposure may cause major congenital malformations. Second and third trimester exposure may cause fetal renal impairment and oligohydramnios. Effective contraception must be used during treatment and for 1 month after cessation. |
| Fetal Monitoring | Pregnancy testing is required before initiation and monthly during therapy. Monitor fetal ultrasound and amniotic fluid volume if pregnancy occurs. Contraceptive adherence must be confirmed at each visit. |
| Fertility Effects | FORZINITY may impair fertility in females by disrupting ovarian follicular development. In males, reversible decreases in sperm count and motility have been observed in animal studies. Fertility effects may persist after discontinuation. |
| Clinical Pearls | FORZINITY is a sodium-glucose cotransporter-2 (SGLT2) inhibitor indicated for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Monitor renal function before initiation and periodically; avoid if eGFR < 30 mL/min/1.73 m². Assess volume status in elderly or patients on diuretics. Educate patients on risk of euglycemic diabetic ketoacidosis (DKA) even with normal blood glucose. Discontinue before scheduled surgery or during serious illness. Do not use with insulin in type 1 diabetes due to DKA risk. |
| Patient Advice | Take this medication once daily, with or without food. · Drink plenty of fluids to prevent dehydration and avoid excessive alcohol consumption. · Report symptoms of urinary tract infections (burning, frequency) or genital yeast infections (itching, discharge). · Seek immediate medical attention if you experience nausea, vomiting, abdominal pain, unusual sleepiness, or difficulty breathing, which may be signs of a rare but serious condition called ketoacidosis. · Check your blood sugar regularly and carry fast-acting glucose for hypoglycemia if on insulin or sulfonylurea. · Tell your doctor if you become pregnant or plan to breastfeed. · Inform all healthcare providers you are taking this medication before surgery or procedures. |